How Will the Predictive And Presymptomatic Testing Market Grow? Key Trends and Opportunities for 2025 and Beyond
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
How has the predictive and presymptomatic testing market grown in recent years?
In recent times, the scale of the predictive and presymptomatic testing market has seen swift expansion. The market, valued at $5.24 billion in 2024, is projected to increment to $5.78 billion in 2025, indicating a compound annual growth rate (CAGR) of 10.3%. The monumental growth witnessed in the historical phase is credited to the escalating occurrences of genetic conditions, amplified demand for early detection of chronic illnesses, a surge in cancer prevalence, heightened acceptance of personalized medication, and an increasing supply of direct-to-consumer genetic tests.
How is the predictive and presymptomatic testing market size expected to evolve during the forecast period?
The market size for predictive and presymptomatic testing is set to experience accelerated growth in the ensuing years, projecting to reach $8.47 billion by 2029, at a compound annual growth rate (CAGR) of 10.1%. This prospective rise within the forecast period is attributed to factors including the surge in the demand for earlier disease identification, escalation in biotechnology and genomics investments, growing preference for non-invasive testing procedures, the expanding older population, and an increase in precision medicine initiatives. Key trends anticipated within the forecast period comprise the uptake of personalized medicine, the growing use of home testing kits, the fusion of genomics and big data, the advancement of next-generation sequencing (NGS) technologies, and the application of predictive testing in drug development.
Get your predictive and presymptomatic testing market report here!
Which key drivers are propelling the predictive and presymptomatic testing market’s growth?
The escalating occurrence of genetic conditions is predicted to drive the growth of the predictive and presymptomatic testing market. Genetic conditions, such as cystic fibrosis and down syndrome, arise due to abnormalities in the deoxyribonucleic acid (DNA), which include gene mutations and changes in chromosomes. The growth in the incidence rate of these genetic illnesses is being driven by factors such as mature maternal age, environmental contributors, and enhanced diagnostic methods. Predictive and presymptomatic testing is critical in decreasing the occurrence rates of these genetic diseases by identifying at-risk individuals before the appearance of symptoms. This anticipatory strategy enables early intervention or alterations in lifestyle that can assist in avoiding or reducing the severity of these illnesses. For example, in June 2023, the American Society of Gene and Cell Therapy – a US-based nonprofit medical and scientific association – reported that the number of gene therapies in Phase III clinical trials rose by 10% in the third quarter of 2023. This was the first such upturn since the third quarter of 2022. Therefore, the increased occurrence of genetic maladies is fuelling the growth of the predictive and presymptomatic testing market.
What are the market segments in the predictive and presymptomatic testing industry?
The predictive and presymptomatic testing market covered in this report is segmented –
1) By Test Type: Predictive Testing, Presymptomatic Testing
2) By Application: Cancer Genetic Testing, Cardiovascular Genetic Testing, Neurological Genetic Testing, Other Applications
3) By End User: Hospitals And Clinics, Diagnostic Laboratories, Research Institutes, Other End Users
Subsegments:
1) By Predictive Testing: Genetic Testing for Inherited Conditions, Cancer Risk Prediction, Cardiovascular Disease Prediction, Neurodegenerative Disease Risk Prediction, Genetic Screening for Autosomal Dominant Disorders, Prenatal Predictive Testing, Pharmacogenomic Testing
2) By Presymptomatic Testing: Huntington’s Disease Testing, Hereditary Cancer Risk Testing, Cystic Fibrosis Presymptomatic Testing, Early-Onset Alzheimer’s Disease Testing, Carrier Screening for Genetic Conditions, Testing for Early Signs of Neurodegenerative Diseases, Presymptomatic Genetic Testing for Familial Diseases
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20594&type=smp
Which leading companies are shaping the growth of the predictive and presymptomatic testing market?
Major companies operating in the predictive and presymptomatic testing market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Mayo Clinic, Quest Diagnostics Inc., Illumina Inc., Bio-Rad Laboratories Inc., Qiagen N.V., Peter MacCallum Cancer Centre, Myriad Genetics Inc., SomaLogic Inc., Siteman Cancer Center, Dante Labs S.R.L., Mapmygenome, Manipal Health Enterprises, Gene Vision, Reliance Diagnostic, GenepoweRx, Personal Genomics, Apollo Hospitals Enterprise Limited, Cardio Diagnostics Inc.
What key trends are currently impacting the predictive and presymptomatic testing market’s development?
Leading firms in the predictive and presymptomatic testing market are designing unique tests like multigene testing. This innovative diagnostic technique assesses numerous genes at the same time to identify any potential health threats, paving the way for timely preemptive measures. Multigene testing studies several genes concurrently to discover genetic variations or mutations that might be related to specific conditions or diseases, thus assisting in personalized medical care and strategic treatment plans. For example, in July 2022, biotechnology research firm Genetic Technologies Limited based in Australia, collaborated with Siles Health, a women’s health center in Australia, to introduce the geneType Multi-Risk Test. This all-inclusive tool assesses the risk of a patient contracting various major diseases like breast cancer, colorectal cancer, and type 2 diabetes. It examines both inherited and random genetic factors with the aim of structuring personalized healthcare plans and facilitating early interventions.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20594
Which geographic areas are influencing the growth of the predictive and presymptomatic testing market?
North America was the largest region in the predictive and presymptomatic testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the predictive and presymptomatic testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Predictive Vehicle Technology Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/predictive-vehicle-technology-global-market-report
Predictive Analytics Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/predictive-analytics-global-market-report
Predictive Maintenance Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/predictive-maintenance-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
